Overview

It is PAION's vision to become the acknowledged "PAIONeer" in sedation and anesthesia, through direct commercialization and successful partnerships. In the course of ongoing development activities PAION entered into numerous partnerships with development partners. 

PAION concentrates its development activities on its lead substance Remimazolam. All other R&D activities are done by our partners. Further details of current partnerships can be found under Partnering.